Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/20/2026, 12:00:00 AM
U.S. FDA approved Opdivo (nivolumab) in combination with AVD for the first-line treatment of adult and pediatric patients with previously untreated, Stage III or IV classical Hodgkin Lymphoma.
Korean Translation
미국 FDA, 이전에 치료받지 않은 3기 또는 4기 전형적 호지킨 림프종 성인 및 소아 환자의 1차 치료를 위해 옵디보(니볼루맙)와 AVD 병용 요법을 승인함.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
RELX PLC (RELX) · Other
Ex-dividend date for the 48.0 pence per share final dividend for fiscal year 2025 on May 7, 2026; dividend-related price adjustments are typically low, scheduled
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Leidos is scheduled to release Q1 2026 financial results on May 5, 2026, with analysts forecasting EPS of $2.91-$2.94 expected.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer's Q1 2026 earnings release is scheduled for May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM